{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:08:12Z","timestamp":1762459692544},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12916-019-1289-6","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T02:04:19Z","timestamp":1551751459000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?"],"prefix":"10.1186","volume":"17","author":[{"given":"Richard","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"1289_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrc748","volume":"2","author":"MT Little","year":"2002","unstructured":"Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer. 2002;2:231\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1289_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell."},{"key":"1289_CR3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917\u201320.","journal-title":"Science."},{"key":"1289_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.4313","volume":"23","author":"TI Cornu","year":"2017","unstructured":"Cornu TI, Mussolino C, Cathomen T. Refining strategies to translate genome editing to the clinic. Nat Med. 2017;23:415\u201323.","journal-title":"Nat Med"},{"key":"1289_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"1289_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14760584.2018.1541743","volume":"17","author":"JL Tanyi","year":"2018","unstructured":"Tanyi JL, George E. Personalized vaccination against ovarian cancer: what are the possibilities? Expert Rev Vaccines. 2018;17:955\u20138.","journal-title":"Expert Rev Vaccines"},{"key":"1289_CR7","doi-asserted-by":"publisher","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","volume":"8","author":"J Rosenblatt","year":"2016","unstructured":"Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016;8:368ra171.","journal-title":"Sci Transl Med"},{"key":"1289_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/86498","volume":"7","author":"AA Kocher","year":"2001","unstructured":"Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430\u20136.","journal-title":"Nat Med"},{"key":"1289_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/nm912","volume":"9","author":"AA Mangi","year":"2003","unstructured":"Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195\u2013201.","journal-title":"Nat Med"},{"key":"1289_CR10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1161\/01.CIR.0000034046.87607.1C","volume":"106","author":"BE Strauer","year":"2002","unstructured":"Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913\u20138.","journal-title":"Circulation."},{"key":"1289_CR11","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1161\/01.CIR.0000043246.74879.CD","volume":"106","author":"B Assmus","year":"2002","unstructured":"Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009\u201317.","journal-title":"Circulation."},{"key":"1289_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0140-6736(00)03617-5","volume":"357","author":"P Menasche","year":"2001","unstructured":"Menasche P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279\u201380.","journal-title":"Lancet."},{"key":"1289_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tmrv.2015.11.004","volume":"30","author":"MJ Fontaine","year":"2016","unstructured":"Fontaine MJ, Shih H, Schafer R, Pittenger MF. Unraveling the mesenchymal stromal cells\u2019 paracrine immunomodulatory effects. Transfus Med Rev. 2016;30:37\u201343.","journal-title":"Transfus Med Rev"},{"key":"1289_CR14","first-page":"9601623","volume":"2018","author":"C Zhao","year":"2018","unstructured":"Zhao C, Ikeya M. Generation and applications of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Int. 2018;2018:9601623.","journal-title":"Stem Cells Int"},{"key":"1289_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/stem.1386","volume":"31","author":"R Jitschin","year":"2013","unstructured":"Jitschin R, Mougiakakos D, Von BL, Volkl S, Moll G, Ringden O, et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells. 2013;31:1715\u201325.","journal-title":"Stem Cells"},{"key":"1289_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","volume":"17","author":"A Trounson","year":"2017","unstructured":"Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2017;17:11\u201322.","journal-title":"Cell Stem Cell"},{"key":"1289_CR17","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.3389\/fimmu.2018.02056","volume":"9","author":"A Leyendecker Jr","year":"2018","unstructured":"Leyendecker A Jr, Pinheiro CCG, Amano MT, Bueno DF. The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review. Front Immunol. 2018;9:2056.","journal-title":"Front Immunol"},{"key":"1289_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jcyt.2012.10.002","volume":"15","author":"J Galipeau","year":"2013","unstructured":"Galipeau J. The mesenchymal stromal cells dilemma \u2013 does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15:2\u20138.","journal-title":"Cytotherapy."},{"key":"1289_CR19","first-page":"CD009768","volume":"1","author":"SA Fisher","year":"2019","unstructured":"Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019;1:CD009768.","journal-title":"Cochrane Database Syst Rev"},{"key":"1289_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2014.41","volume":"28","author":"L Kordelas","year":"2014","unstructured":"Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970\u20133.","journal-title":"Leukemia."},{"key":"1289_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","volume":"53","author":"P Bader","year":"2018","unstructured":"Bader P, Kuci Z, Bakhtiar S, Basu O, Bug G, Dennis M, et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant. 2018;53:852\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"1289_CR22","doi-asserted-by":"publisher","first-page":"eaam7828","DOI":"10.1126\/scitranslmed.aam7828","volume":"9","author":"A Galleu","year":"2017","unstructured":"Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017;9:eaam7828.","journal-title":"Sci Transl Med"},{"key":"1289_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12916-015-0426-0","volume":"13","author":"N D\u2019souza","year":"2015","unstructured":"D\u2019souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, et al. Mesenchymal stem\/stromal cells as a delivery platform in cell and gene therapies. BMC Med. 2015;13:186.","journal-title":"BMC Med"},{"key":"1289_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000447458","volume":"43","author":"R Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer R, Spohn G, Baer PC. Mesenchymal stem\/stromal cells in regenerative medicine: can preconditioning strategies improve therapeutic efficacy? Transfus Med Hemother. 2016;43:256\u201367.","journal-title":"Transfus Med Hemother"},{"key":"1289_CR25","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1089\/scd.2011.0626","volume":"21","author":"G Siegel","year":"2012","unstructured":"Siegel G, Krause P, Wohrle S, Nowak P, Ayturan M, Kluba T, et al. Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev. 2012;21:2457\u201370.","journal-title":"Stem Cells Dev"},{"key":"1289_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/stem.2575","volume":"35","author":"DG Phinney","year":"2017","unstructured":"Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35:851\u20138.","journal-title":"Stem Cells"},{"key":"1289_CR27","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s00253-018-8912-x","volume":"102","author":"V Jossen","year":"2018","unstructured":"Jossen V, van den Bos C, Eibl R, Eibl D. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Appl Microbiol Biotechnol. 2018;102:3981\u201394.","journal-title":"Appl Microbiol Biotechnol"},{"key":"1289_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.tibtech.2018.01.005","volume":"36","author":"A Ovsianikov","year":"2018","unstructured":"Ovsianikov A, Khademhosseini A, Mironov V. The synergy of scaffold-based and scaffold-free tissue engineering strategies. Trends Biotechnol. 2018;36:348\u201357.","journal-title":"Trends Biotechnol"},{"key":"1289_CR29","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1111\/trf.13561","volume":"56","author":"R Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer R, Bieback K. Characterization of mesenchymal stem or stromal cells: tissue sources, heterogeneity, and function. Transfusion. 2016;56:2S\u20135S.","journal-title":"Transfusion."},{"key":"1289_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1741-7015-11-146","volume":"11","author":"G Siegel","year":"2013","unstructured":"Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schafer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.","journal-title":"BMC Med"},{"key":"1289_CR31","first-page":"41","volume":"7","author":"RC Rennert","year":"2016","unstructured":"Rennert RC, Schafer R, Bliss T, Januszyk M, Sorkin M, Achrol AS, et al. High-resolution microfluidic single-cell transcriptional profiling reveals clinically relevant subtypes among human stem cell populations commonly utilized in cell-based therapies. Front Neurol. 2016;7:41.","journal-title":"Front Neurol"},{"key":"1289_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/stem.2934","volume":"37","author":"SML Khong","year":"2019","unstructured":"Khong SML, Lee M, Kosaric N, Khong DM, Dong Y, Hopfner U, et al. Single-Cell Transcriptomics of Human Mesenchymal Stem Cells Reveal Age-Related Cellular Subpopulation Depletion and Impaired Regenerative Function. Stem Cells. 2019;37:240\u20136.","journal-title":"Stem Cells"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-019-1289-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:16:15Z","timestamp":1583280975000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-019-1289-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1186\/s12916-019-1289-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that he has no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"53"}}